A citation-based method for searching scientific literature

B Wang, J Zhong, H Lin, Z Zhao, Z Yan, H He, Y Ni, D Liu, Z Zhu. Diabetes Obes Metab 2013
Times Cited: 126



John B Buse, Julio Rosenstock, Giorgio Sesti, Wolfgang E Schmidt, Eduard Montanya, Jason H Brett, Marcin Zychma, Lawrence Blonde. Lancet 2009
Times Cited: 1040




List of shared articles



Times cited



Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists.
C Berra, R Manfrini, D Regazzoli, M G Radaelli, O Disoteo, C Sommese, P Fiorina, G Ambrosio, F Folli. Pharmacol Res 2020
5


An overview of glucagon-like peptide-1 receptor agonists for the treatment of metabolic syndrome: A drug repositioning.
Maryam Rameshrad, Bibi Marjan Razavi, Jean-Daniel Lalau, Marc E De Broe, Hossein Hosseinzadeh. Iran J Basic Med Sci 2020
2

Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force.
Sanjay Kalra, Ashok Kumar Das, Rakesh Kumar Sahay, Manash Pratim Baruah, Mangesh Tiwaskar, Sambit Das, Sudip Chatterjee, Banshi Saboo, Ganapathi Bantwal, Saptarshi Bhattacharya,[...]. Diabetes Ther 2019
8

Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes.
Gül Bahtiyar, Jean Pujals-Kury, Alan Sacerdote. Curr Diab Rep 2018
14

PRISMA-efficacy and safety of lixisenatide for type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
Zhen-Gang Wei, Man-Cai Wang, Hui-Han Zhang, Zhe-Yuan Wang, Gen-Nian Wang, Feng-Xian Wei, Ya-Wu Zhang, Xiao-Dong Xu, You-Cheng Zhang. Medicine (Baltimore) 2018
0

Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies.
Junfeng Li, Juan Zheng, Susanne Wang, Harry K Lau, Ali Fathi, Qinghua Wang. Front Physiol 2017
19


GLP-1 Agonists and Blood Pressure: A Review of the Evidence.
Aditya Goud, Jixin Zhong, Matthew Peters, Robert D Brook, Sanjay Rajagopalan. Curr Hypertens Rep 2016
37

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists.
Yu Mi Kang, Chang Hee Jung. Endocrinol Metab (Seoul) 2016
25


Glucagon-like peptide-1 receptor agonists favorably address all components of metabolic syndrome.
Sanjay Chatterjee, Samit Ghosal, Saurav Chatterjee. World J Diabetes 2016
11

Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials.
Bin Su, Hui Sheng, Manna Zhang, Le Bu, Peng Yang, Liang Li, Fei Li, Chunjun Sheng, Yuqi Han, Shen Qu,[...]. Endocrine 2015
99

Twelve-month treatment with Liraglutide ameliorates Visceral Adiposity Index and common cardiovascular risk factors in type 2 diabetes outpatients.
G T Russo, A M Labate, A Giandalia, E L Romeo, P Villari, A Alibrandi, G Perdichizzi, D Cucinotta. J Endocrinol Invest 2015
26

Cardiometabolic Effects of a New Class of Antidiabetic Agents.
Cyrus V Desouza, Namita Gupta, Anery Patel. Clin Ther 2015
27

Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic Medications.
C A Alvarez, I Lingvay, V Vuylsteke, R L Koffarnus, D K McGuire. Clin Pharmacol Ther 2015
21

Case Study: Use of GLP-1 Receptor Agonist in a Patient on Intensive Insulin Therapy.
Kenneth Calvin Wiley, Ranti Akiyode, Gail Nunlee-Bland. Diabetes Spectr 2015
1

Incretin-based therapies for obesity treatment.
Aline Haas de Mello, Morgana Prá, Larissa Colonetti Cardoso, Rosiane de Bona Schraiber, Gislaine Tezza Rezin. Metabolism 2015
19